Study tacrolimus levels after liver transplant
Treatments studied
Part of Digestive system clinical trials.
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a liver transplant (or a liver and kidney transplant at the same time)
- You have been taking a tacrolimus medicine for at least 4 weeks, and your level is between 5 and 20 ng/mL before starting
- Your tacrolimus blood level will be considered only if you consent to use your de-identified medical data
- You have not been in another clinical trial in the last 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if switching from a standard twice-daily tacrolimus to a once-daily prolonged-release version is safe and effective for liver transplant recipients who have stable liver function. It aims to simplify your medication schedule.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
Hear when a new Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.